Filing Flows › Adma Biologics (ADMA) › Operating margin
Adma Biologics (ADMA) operating margin by quarter
Adma Biologics' operating margin was 48.0% in Q3 2026 (third quarter 2026), +5.9 pts from Q2 2026. Over the last 7 quarters it ranged from 30.4% (Q1 2025) to 50.9% (Q1 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 48.0% | +5.9 pts | +10.0 pts |
| Q2 2026 | 42.2% | -8.7 pts | +7.1 pts |
| Q1 2026 | 50.9% | +5.8 pts | +20.5 pts |
| Q4 2025 | 45.1% | +7.1 pts | — |
| Q3 2025 | 38.0% | +2.9 pts | — |
| Q2 2025 | 35.1% | +4.7 pts | — |
| Q1 2025 | 30.4% | — | — |
Q3 2026 at a glance
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adma Biologics' operating margin?
Adma Biologics' operating margin was 48.0% in Q3 2026 (third quarter 2026), +5.9 pts from Q2 2026.
How has Adma Biologics' operating margin changed?
Over the last 7 quarters it ranged from 30.4% (Q1 2025) to 50.9% (Q1 2026).